Skip To Main Content
Roxanne Khamsi on Muck Rack

Roxanne Khamsi

As seen in: The Atlantic, LinkedIn, Elemental, MSN, O Globo, The New York Times, The New York Times Magazine, Nature, Nature Medicine, TIME, Yahoo News and
contributing writer @TheAtlantic - author of BEYOND INHERITANCE, available now: amazon.com/dp/059354191X Free alerts: roxanne.substack.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Roxanne

Contact Roxanne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The life-saving DNA of genetic outliers

|
By Roxanne Khamsi
| Substack
Around a decade ago, Ludivine Verboogen and Romain Alderweireldt were told their infant son had only months to live. They learned that he had a neonatal form of Marfan syndrome, which causes connective tissue problems and deadly heart complications. The couple were desperate for clues about what could help their young child, so they started reading as much as they could about people with inherited disorders.
Open in Who Shared Issue with article?

The Genes That Could Cancel Out a Fatal Diagnosis

|
By Roxanne Khamsi
| The Atlantic Verified
When Ludivine Verboogen and Romain Alderweireldt’s third child was born in Belgium in late 2015, they marveled at his long fingers. Perhaps one day he will be a famous pianist, they thought. But soon Ludivine grew worried that her son was not developing as well as his two older sisters had. His muscles seemed weak, and the physiotherapy appointments she was taking him to three times a week didn’t seem to be helping.
Open in Who Shared View Duplicates (3) Issue with article?

Scientific American

|
By Roxanne Khamsi
| Scientific American Verified
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder In late 2021, Amber Salzman interviewed for a job that she had no intention of taking. A relatively new start-up company, called Epicrispr Biotechnologies, was looking for a chief executive, and it was keen on vetting Salzman — who had decades of experience in the pharmaceutical industry — for the role.
Open in Who Shared View Duplicates (2) Issue with article?
See all 178 licensed articles (205 Total)